CIGB-258 a peptide derived from human heat-shock protein 60 decreases hyperinflammation in COVID-19 patients

摘要

Diagram of CIGB-258 therapy. CIGB-258 treatment for critically ill patients (blue line) consisted of 2 mg every 12 h. After extubation, the patients received 1 mg of CIGB-258 daily for another 3 days. Seriously ill patients (red line) were treated with 1mg of CIGB-258 every 12 h, until they resolved their serious clinical condition. Seriously ill obese patients started therapy with 2mg of CIGB-258 every 12 h. The peptide was administered intravenously